Boston Scientific Corporation $BSX Position Lifted by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 15.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,497 shares of the medical equipment provider’s stock after acquiring an additional 32,425 shares during the period. Union Bancaire Privee UBP SA’s holdings in Boston Scientific were worth $23,417,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Steph & Co. bought a new position in shares of Boston Scientific during the third quarter worth about $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp raised its stake in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter worth approximately $26,000. Finally, United Community Bank grew its position in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on BSX shares. TD Cowen dropped their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Truist Financial reduced their price target on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a research report on Wednesday. National Bank Financial set a $115.00 price target on shares of Boston Scientific in a report on Monday, February 2nd. Finally, BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $107.18.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Truist kept a “buy” rating while trimming its price target to $92, signifying continued analyst confidence in BSX’s longer-term growth despite a modest cut to near-term expectations. Read More.
• Positive Sentiment: Analyst commentary and screeners continue to list Boston Scientific as a defensive healthcare pick amid broader market volatility, supporting demand from investors seeking lower-correlation names. Read More.
• Neutral Sentiment: Health-care indices were softer in late trading today, which weighs on BSX alongside peers but reflects sector-wide pressure rather than company-specific fundamentals. Read More.
• Neutral Sentiment: Relative performance: Boston Scientific underperformed some competitors in today’s session, signalling short-term selling pressure versus the group. Read More.
• Negative Sentiment: Boston Scientific amended its recall for Accolade pacemakers, expanding the affected population to about 1.6 million devices and updating related software remediation — a material safety/recall development that raises regulatory, replacement and reputational risks. Read More.
• Negative Sentiment: The New York Times reported Boston Scientific had internal test results in 2025 showing an “extremely high failure rate” for some pacemaker batteries and that management knew of battery problems for years — a disclosure likely increasing litigation and regulatory scrutiny. Read More.
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities-class-action lawsuits tied to disclosures (class period Jul 23, 2025–Feb 3, 2026), and several investor-alerts remind shareholders of an early-May deadline to seek lead-plaintiff status — increasing legal risk and potential costs. Read More.
• Negative Sentiment: Additional analyst downgrades/expectation cuts (UBS among them) have lowered near-term estimates, compounding downward pressure on the stock while investors reassess guidance and litigation/recall impacts. Read More.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $70.04 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market capitalization of $103.93 billion, a PE ratio of 36.10, a P/E/G ratio of 1.00 and a beta of 0.69. Boston Scientific Corporation has a 1-year low of $67.56 and a 1-year high of $109.50. The business’s fifty day moving average price is $80.31 and its two-hundred day moving average price is $92.40.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.